Primary Record
MRE-269
- In stock
- 9,699 g
- Purity
- 99.5 %
- CAS
- 475085-57-5
Compound Identifiers & Properties
- CAS
- 475085-57-5
- PubChem CID
- 9931891
- SMILES
- CC(C)N(CCCCOCC(=O)O)C1=CN=C(C(=N1)C2=CC=CC=C2)C3=CC=CC=C3
- Canonical SMILES
- CC(C)N(CCCCOCC(=O)O)c1cnc(-c2ccccc2)c(-c2ccccc2)n1
Names & Synonyms
- MRE-269
- 475085-57-5
- Laselipag
- Selexipag Acid
- laselipag [INN]
- ACT-333679
- Selexipag Impurity 1
- Selexipag Impurity 2
- MRE269
- UNII-E9PC7N0DID
- E9PC7N0DID
- Selexipag active metabolite
- MRE 269
- RefChem:552102
- ACT 333679
- CHEMBL239226
- C25H29N3O3
- ACT333679
- CHEBI:90848
- SCHEMBL676234
- MFCD11976884
- OJQMKCBWYCWFPU-UHFFFAOYSA-N
- DTXSID801153092
- GTPL5852
- orb1303362
- SCHEMBL29355314
- 2-(4-((5,6-diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)acetic acid
- DTXCID401584623
- GLXC-04713
- HMS3748O13
- BCP16833
- MRE-269?
- ZINC1553986
- ARD193950
- BDBM50235387
- EBC-53056
- s5819
- AKOS027307832
- J2.120.976G
- CID9931891
- CS-6104
- SB19699
- (4-((5,6-Diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)acetic acid
- NCGC00476132-02
- AK289388
- AS-72199
- HY-79593
- MRE-269(ACT-333679)
- DB-119492
- MRE-269 (ACT-333679)
- Y0263
- EN300-384328
- Z-3153
- [4-[(5,6-DIPHENYLPYRAZINYL)(1-METHYLETHYL)AMINO]BUTOXY]-ACETIC ACID
- 144382-EP2289518A1
- 144382-EP2292231A1
- 2-[4-[(5,6-diphenylpyrazin-2-yl)-propan-2-ylamino]butoxy]acetic acid
- 2-{4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}acetic acid
- A857157
- {4-[(5,6-Diphenyl-2-pyrazinyl)(isopropyl)amino]butoxy}acetic acid
- {4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}acetic acid
- BRD-K57391913-001-01-4
- Q27087731
- B0084-475745
- 2-[4-[(5,6-Diphenyl-2-pyrazinyl)(1-methylethyl)amino]butoxy]acetic acid
- 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}acetic acid
- (4-((5,6-diphenylpyrazinyl)(1-methylethyl)amino)butoxy)acetic acid
- [4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]acetic acid
- {4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid
- 2-[4-[Isopropyl(5,6-diphenylpyrazine-2-yl)amino]butoxy]acetic acid
- ACT-333679;MRE269;MRE 269;ACT333679;ACT 333679
- (4-((5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino)butoxy)acetic acid
- (4-((5,6-Diphenylpyrazinyl)(1-methylethyl)amino)butoxy)-acetic acid
- 2-(4-((5,6-Diphenyl-2-pyrazinyl)(1-methylethyl)amino)butoxy)acetic acid
- 2-(4-(ISOPROPYL(5,6-DIPHENYLPYRAZINE-2-YL)AMINO)BUTOXY)ACETIC ACID
- 2-[4-[(5,6-diphenylpyrazin-2-yl)-isopropyl-amino]butoxy]acetic acid
- 2-[4-[(5,6-diphenylpyrazin-2-yl)-propan-2-yl-amino]butoxy]acetic Acid
- 2-[4-[(5,6-diphenylpyrazin-2-yl)-propan-2-yl-amino]butoxy]ethanoic acid
- 2-[4-[(5,6-Diphenylpyrazine-2-yl)-propane-2-ylamino]butoxy]acetic acid
- 2-[4-[[5,6-di(phenyl)pyrazin-2-yl]-propan-2-ylamino]butoxy]acetic acid
- Acetic acid, [4-[(5,6-diphenylpyrazinyl)(1-methylethyl)amino]butoxy]-
- Acetic acid, 2-[4-[(5,6-diphenyl-2-pyrazinyl)(1-methylethyl)amino]butoxy]-
- [4-[(5,6-Diphenylpyrazinyl)(1-methylethyl)amino]butoxy]-acetic Acid; 2-[4-[(5,6-Diphenyl-2-pyrazinyl)(1-methylethyl)amino]butoxy]acetic Acid;ACT 333679; [4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]acetic Acid; MRE-269
- Y9Q